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Abstract
The preferred treatment for hypothyroidism is oral levothyroxine (LT4) ingestion, in doses that ensure a sustained state of hormonal bal-
ance. Many different factors may significantly influence the absorption of LT4, including: interval between the ingestion of the drug and 
the last meal, eating habits, and different functional and organic pathologies of the gastro-intestinal tract.
The main purpose of this paper is to review and systematise the available literature on the subject of the influence of different malabsorp-
tion syndromes on the effectiveness of LT4 preparations.
The need to use high LT4 doses in the substitutional treatment of hypothyroidism is often the very first sign of one of the pathologies that 
are connected with malabsorption syndrome, which might have been asymptomatic and undiagnosed previously. Patients who require 
more than 2 μg/kg body weight of LT4 per day, with constantly increased thyrotropin level, should be diagnosed with the suspicion of 
pseudomalabsorption or real absorption disorder. An LT4 absorption test, using high doses of LT4, may be useful in the diagnosis of pseu-
domalabsorption. After excluding non-compliance, the differential diagnosis should include such disorders as lactose intolerance, coeliac 
disease, atrophic gastritis, Helicobacter pylori infection, bowel resection, inflammatory bowel disease, and parasite infection.
Where there is a diagnosis of lactose intolerance, both a low lactose diet and a lactose-free LT4 preparation should be administered to restore 
euthyroidism or make it possible to decrease the dose of the LT4 preparation. In coeliac disease, a gluten-free diet usually allows a normalisation 
of the need for LT4, as do eradication of the H. pylori infection or parasite colonisation. In cases of atrophic gastritis or inflammatory bowel disease, 
treating the underlying diseases and regaining the state of remission may improve the absorption of LT4. In patients after gastro-intestinal tract 
surgery, a dose of LT4 higher than that typically used is needed to restore euthyroidism. (Endokrynol Pol 2012; 63 (4): 318–323)
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Streszczenie
Metodą z wyboru w leczeniu niedoczynności tarczycy jest doustne podawanie L-tyroksyny (LT4) w dawkach pozwalających na utrzymanie 
u pacjenta stanu równowagi hormonalnej. Wymienia się wiele czynników, które mogą w istotny sposób wpływać na wchłanianie prepa-
ratu LT4, do których należą między innymi: korelacja czasowa przyjęcia leku i ostatniego posiłku, niektóre nawyki żywieniowe, a także 
różne organiczne i czynnościowe patologie przewodu pokarmowego. Głównym celem niniejszej pracy jest przegląd i usystematyzowanie 
literatury dotyczącej wpływu różnorodnych zaburzeń wchłaniania na skuteczność podawanych preparatów LT4.
Konieczność stosowania dużych dawek LT4 w leczeniu substytucyjnym niedoczynności tarczycy często jest pierwszym objawem jednego 
z zespołów chorobowych, przebiegających z zaburzeniami wchłaniania, które mogą być skąpoobjawowe i wcześniej mogły pozostawać 
nierozpoznane. Pacjenci otrzymujący LT4 w dawce większej niż 2 μg/kg mc./dobę, z przetrwale podwyższonymi stężeniami tyreotropiny, 
powinni być poddani diagnostyce w kierunku pozornych lub rzeczywistych zaburzeń wchłaniania LT4. Test wchłaniania LT4 z wyko-
rzystaniem jej dużej dawki jest przydatny w diagnozie pozornych zaburzeń wchłaniania. Po wykluczeniu braku współpracy ze strony 
pacjenta w diagnostyce różnicowej należy uwzględnić takie patologie, jak: nietolerancja laktozy, celiakia, zanikowe zapalenie błony śluzowej 
żołądka, infekcja Helicobacter pylori, stan po resekcji jelita, nieswoiste zapalenie jelita czy, wreszcie, infekcje pasożytnicze.
W przypadku potwierdzenia nietolerancji laktozy należy zastosować preparat LT4 pozbawiony laktozy oraz dietę bezlaktozową w celu uzyskania 
eutyreozy bądź możliwości zmniejszenia dawki preparatu LT4. W celiakii zastosowanie diety bezglutenowej zwykle skutkuje normalizacją zapotrze-
bowania na LT4, podobnie jak eradykacja infekcji bakteryjnej H. pylori czy pasożytniczej. W przypadku zanikowego zapalenia błony śluzowej żołądka 
czy nieswoistego zapalenia jelita leczenie choroby podstawowej i uzyskanie remisji może doprowadzić do poprawy wchłaniania LT4. U chorych po 
operacjach jelit zwykle konieczne jest stosowanie ponadstandardowych dawek LT4 w celu uzyskania eutyreozy. (Endokrynol Pol 2012; 63 (4): 318–323)
Słowa kluczowe: niedoczynność tarczycy, L-tyroksyna, zaburzenia wchłaniania, nietolerancja laktozy, celiakia
Introduction
Irrespective of the cause, the external replacement of 
hormonal deficiency constitutes the basic method of hy-
pothyroidism treatment. Oral preparations available com-
mercially contain as an active substance either L-thyroxine 
(LT4) sodium or its combination with L-triiodothyronine. 
The method of choice in hypothyroidism treatment is oral 
administration of LT4 in doses that enable the patient’s 
hormonal balance to be maintained [1].
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There are many difficulties in obtaining and sustain-
ing euthyroidism in a hypothyroid patient that a practic-
ing clinician may come across. In patients treated with 
a standard LT4 dose, when a state of compensation is 
not achieved, two potential causes of the phenomenon 
should be considered: firstly, patient non-compliance, 
and secondly, drug malabsorption in the alimentary tract.
Patient non-compliance, also referred to as pseu-
domalabsorption, remains the most frequent cause of 
failure to achieve euthyroidism despite large doses of 
LT4 (> 2 μg/kg body weight).
L-thyroxine is absorbed from the lumen of the 
alimentary tract within hours from the moment of 
administration, mainly in the jejunum and ileum and, 
to a lesser degree, in the duodenum. Of crucial impor-
tance is the role of acidity of gastric juice; therefore, it is 
recommended that preparations be taken on an empty 
stomach to maximise the dose absorbed [2, 3].
There are many factors that can significantly affect 
LT4 absorption, such as the time elapsed between the 
drug administration and the last meal, certain eating 
habits, as well as various organic and functional patholo-
gies of the alimentary tract.
It has been proven that absorption is optimal when 
LT4 is taken on an empty stomach, whereas it is not so 
effective when the preparation is administered directly 
with a meal [4–6].
As a standard, LT4 should be taken at least 30 min-
utes before breakfast; such a recommendation can be 
found on the leaflets contained in medicine boxes. There 
have also been studies suggesting a similar efficacy of 
the dose taken before going to sleep; the data available, 
however, is not definitive [7, 8].
Drug interactions must also be taken into consid-
eration. Some medications, such as raloxifene, drugs 
binding bile acids, cholestyramine, colestipol, proton 
pump inhibitors, orlistat, sevelamer, and preparations 
containing aluminium, iron or calcium can significantly 
reduce LT4 absorption. Thus it is important that those 
drugs and LT4 should be administered a few hours 
apart [9–15].
A replacement LT4 dose should always be adjusted 
individually. The dose, once established, can be changed 
during treatment, even in the same patient. The factors 
significantly influencing LT4 requirement in a given 
patient include: progress of the disease, an increase 
or decrease in body weight, pregnancy, and the use of 
hormonal drugs such as oral contraception or hormone 
replacement therapy. Moreover, various additional 
ingredients found in different LT4 preparations can 
have an impact on their absorption; therefore, when the 
absorption of the LT4 drug is disturbed, it is well worth 
trying to replace it with another one made by a different 
manufacturer. Studies have shown that LT4 preparations 
made by different manufacturers can have different 
bioavailability [16–18]. However, interpreting some of 
these studies can be difficult owing to, among other 
things, the heterogeneity and the small size of the group 
investigated, a single measurement of drug concentra-
tion in the blood, a different level of hypothyroidism, 
and a lack of correlation in reference to endogenous 
free thyroxine (FT4) concentration. It is because of this 
last-named factor that labelling of the products as bio-
equivalent is not justified. Ignorance of the above fact in 
the procedures recommended by the FDA can result in 
iatrogenic hyper- or hypothyroidism when a preparation 
is replaced without further screening and the establish-
ment of a new dose. The differences in bioavailability 
of preparations of various brands do not result from 
those in the active substance (which is LT4) but from the 
so-called inert ingredients. These, by definition, should 
not have an impact on a patient’s body but, at the same 
time, can considerably modify drug absorption. Lactose 
is frequently used as an adjuvant [19].
The other factors responsible for LT4 absorption are 
eating habits, which result in increased LT4 doses in 
such patients. Grapefruit juice minimally slows down 
LT4 absorption [20], while papaya consumed in large 
amounts has a significantly negative influence on the 
degree of drug bioavailability [21], as does a diet rich in 
fiber [22]. In vitro studies have shown dose-dependent, 
non-specific LT4 absorption by wheat bran and soya 
preparations [23]. On the other hand, it is interesting 
to note that excessive coffee consumption results in 
decreased LT4 absorption [24].
As has already been said, the bioavailability of the 
preparations administered is significantly influenced 
by concomitant organic and functional alimentary tract 
disorders.
The main aim of this paper is a review and systema-
tisation of the literature concerning the impact of dif-
ferent malabsorption phenomena on the effectiveness 
of LT4 preparations.
Lactose intolerance
The frequency of lactose intolerance among adult Cau-
casian patients ranges in the literature from 7% to as 
much as 20% of a population, which makes it a relatively 
common pathology. In Poland, according to different 
studies, hypolactasia in adults occurs in 17.39–37.50% 
of the population. Lactose intolerance (due to intestinal 
lactase deficiency) can be primary (genetics-related) or 
secondary (concomitant with many gastrointestinal 
tract diseases, very often coeliac disease); persistent 
or transient when remission of the main disease can 
reinstate the enzyme’s normal activity and eliminate 
the symptoms of intolerance.
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Primary lactose intolerance occurring in adults 
is inherited autosomally recessively and is the most 
frequent form of lactose deficiency. The activity of the 
enzyme decreases in proportion to age, though total lack 
of lactose production is rare. The presenting symptoms 
(e.g. abdominal discomfort or pain, nausea, vomiting, 
diarrhoea, constipation, flatulence, borborygmus, body 
weight loss) are diverse and non-specific. They are 
derived from lactose fermentation by colon bacteria 
and can often resemble the symptoms of irritable colon 
syndrome. It is worth remembering that irritability to 
lactose is very individual and changes with age [19, 
25, 26].
It should be particularly borne in mind that lactose 
often is the so-called auxiliary ingredient (indifferent, 
as a rule, to the body) used in many commercially avail-
able medicaments [27], and also in those preparations in 
which LT4 is an active substance. Even small amounts 
of lactose in patients with intolerance can result in local 
digestion and absorption disorders, which is unfavour-
able for the absorption of the active substance itself. The 
amount of lactose consumed can be substantial and give 
clinical symptoms, especially in the elderly, in whom 
polypragmasy is not uncommon.
The diagnosis of lactose intolerance is made using 
interview data, an elimination diet and various tests 
(hydrogen test, glucose concentration assessment after 
standardised lactose dose administration, as well as 
small intestine biopsy) [25].
The literature data provides examples of a nega-
tive impact of lactose in medical preparations on 
absorption of various drugs, including psychoactive 
drugs [19]. One example is that of a female patient 
with LT4 malabsorption related to lactose intolerance. 
She had primary hypothyroidism with permanently 
elevated thyrotropin (TSH) levels. When it comes to 
gastrointestinal symptoms, she complained only of 
diarrhoea occurring sporadically over the previous 
7–8 years. Increasing the dose to 900 μg and additional 
therapy with triiodothyronine did not result in the 
restoration of euthyroidism. Malabsorption diagnos-
tic tests, including lactose absorption test, revealed 
lactose intolerance. LT4 intravenous therapy resulted 
in the normalisation of thyroid hormones concen-
trations; then, an LT4 lactose-free preparation and 
a lactose-free diet were used. Three months later, the 
symptoms regressed and biochemical euthyroidism 
was achieved [3].
Coeliac disease
Coeliac disease, an autoimmune ailment of the small 
intestine found in genetically predisposed patients, 
is characterised by chronic dietary gluten intolerance. 
It can manifest itself at any age [26] and the literature 
provides numerous examples of cases in which coeliac 
disease resulted in LT4 malabsorption.
One of the first such cases was a female patient 
after thyreoidectomy who was diagnosed with coeliac 
disease at 68 years of age while being investigated for 
the causes of LT4 and alphacalcidol malabsorption [28]. 
The patient’s history revealed persistent hypocalcaemia, 
chronic diarrhoea, anaemia and hypoalbuminaemia. 
There are also cases of patients in whom LT4 malabsorp-
tion was concomitant with non-specific symptoms of 
coeliac disease such as body weight loss, anaemia, elec-
trolyte disorders (hypocalcaemia, hypomagnesaemia) 
or osteopenia [29, 30]. In some hypothyroid patients 
‘resistance’ to LT4 treatment is the first, and practically 
only, symptom suggestive of malabsorption in coeliac 
disease, with normal haemoglobin, electrolyte and al-
bumin levels and the absence of any clinical indicators 
in the form of gastrointestinal symptoms [31, 32]. In 
all those cases, when a gluten-free diet was employed, 
daily LT4 requirement was reduced and TSH levels 
returned to normal.
A study by Jiskra et al. showed that patients with 
hypothyroidism related to autoimmune thyroiditis, 
in whom the replacement daily LT4 dose was 125– 
–200 μg, presented higher concentrations of anti-gliadin 
IgA antibodies than those in whom the daily LT4 dose 
was lower (50–100 μg) [33].
Virili et al. carried out the first systematic assess-
ment of an LT4 dose in replacement treatment of 
patients with diagnosed hypothyroidism in the course 
of chronic thyroiditis and coeliac disease. The study 
group consisted of 35 patients with hypothyroidism in 
the course of Hashimoto’s thyroiditis and non-classic 
coeliac disease. The analysis focused on the LT4 dose 
necessary to obtain target TSH values before the in-
troduction of a gluten-free diet (in all patients) and 
then in 21 patients on a gluten-free diet (the remain-
ing ones were non-compliant). The LT4 requirement 
was compared to a control group of 68 patients with 
hypothyroidism in the course of Hashimoto’s disease, 
in whom coeliac disease and other ailments that might 
contribute to malabsorption were excluded. In patients 
with isolated hypothyroidism, target TSH values (me-
dian 1.02 mIU/L) were obtained in all persons after 
5 ± 2 months of treatment, with a median daily LT4 
dose of 1.31 μg/kg body weight. At the same time, us-
ing a similar LT4 dose, patients with hypothyroidism 
and coeliac disease manifested higher TSH values 
(median 4.2 mIU/L). In 21 patients, target TSH values 
(median 1.25 mIU/L) were obtained over a period of 
11 ± 3 months of a gluten-free diet; there was no need to 
increase the LT4 dose (median 1.32  μg/kg body weight 
daily). In the remaining 14 patients, who were not on 
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a diet, target TSH values (median 1.54 mIU/L) were 
obtained following an LT4 dose increase (median 1.96 μg/ 
/kg body weight daily, +49%, p < 0.0002) compared 
to patients with hypothyroidism but without coeliac dise- 
ase. The study showed that non-classic coeliac disease 
increased LT4 requirement in replacement therapy and 
that target TSH values can be attained by the introduc-
tion of a gluten-free diet or an increase of LT4 dose. It 
is worth noting that LT4 malabsorption can be the first 
signal of coeliac disease [34].
The problem of concomitant hypothyroidism re-
lated to chronic thyroiditis and coeliac disease is quite 
common, because the underlying factor in both cases is 
an autoimmune process as well as a genetic predisposi-
tion. Thyroid diseases are often accompanied by the 
presence of specific antibodies, including those against 
thyroglobulin, thyreoperoxidase, and TSH receptor, as 
well as such endogenous substances as myosin, tro-
ponin, tropomyosin and myoglobin [35]. It has been 
shown that coeliac disease occurs significantly more of-
ten in patients with Hashimoto’s disease compared to 
the overall population, whereas Hashimoto’s disease, 
in turn, is diagnosed in as many as 21% of patients with 
coeliac disease [36]. Suspected coeliac disease must be 
verified using serological (tissue transglutaminase and 
antiendomysial antibodies) and morphologic tests (en-
doscopic and histopathological confirmation of enteral 
villi atrophy) [26]. The estimated LT4 requirement in to-
tal hypothyroidism is 1.0–2.0 μg/kg body weight daily. 
The values quoted in the paper by Virili et al. come 
within this range, but in patients with concomitant 
coeliac disease they are significantly higher compared 
to those without malabsorption. While increasing 
the LT4 dose in malabsorption patients is not a big 
problem, we think that from a clinical point of view 
it is important to stress the finding that is potentially 
indicative of a diagnosis of non-classic coeliac disease, 
the first noticeable clinical manifestation of which can 
be LT4 malabsorption. Making a diagnosis of classic 
coeliac disease is not usually difficult; however, it is 
the non-classic form, especially without concomitant 
typical gastrointestinal symptoms, diagnosed only in 
adulthood, that does create problems, and very often 
the disease goes undiagnosed for a long time. One 
should remember that in adults with coeliac disease, 
parenteral symptoms are prevalent such as dermal 
symptoms (herpetiform dermatitis), anaemia, geni-
to-urinary tract symptoms (delayed puberty, fertility 
disorders, early menopause), neurological symptoms 
(epilepsy, migraine, depression, ataxia) and other 
(muscle weakness, osteoporosis, tetany, short stature, 
low body weight, enamel hypoplasia). Estimates put 
the ratio of asymptomatic coeliac disease at 1:100–1:300 
in a given population, whereas the classic form of the 
disease with gastrointestinal symptoms is more than 
ten times less frequent [34].
In patients with autoimmune hypothyroidism and 
with no other indications, screening for coeliac disease 
is not recommended. In those, however, in whom 
euthyreosis is attained only after a daily LT4 dose of 
more than 2 μg/kg body weight, tests for coeliac disease 
should be carried out.
In a recent study, Collins et al. compared the 
LT4 requirement in replacement therapy in patients 
with hypothyroidism and concomitant coeliac disease, 
against the requirement in those with isolated hypo-
thyreosis. The study showed that the LT4 requirement 
in the former group, before introduction of a gluten-free 
diet, was 2.6 μg/kg body weight compared to 1.3 μg/kg 
body weight in the latter group, with coeliac disease 
treatment resulting in a significant decrease in LT4 re-
quirement to 1.89 μg/kg body weight [37].
Atrophic gastritis  
and Helicobacter pylori infection
Chronic atrophic gastritis is another common factor 
modifying LT4 absorption. It is connected with gastric 
mucosa colonisation by H. pylori, and could affect as 
much as 50% of the world’s population. The main 
source of LT4 malabsorption in this case is the reduced 
acidity of gastric juice. During H. pylori infection, urease 
produced by the microorganisms neutralises the acidity 
of gastric juice [38]. Centanni et al. have proven that 
patients with multinodular goitre and H. pylori infection 
(a 22% increase), with atrophic gastritis (a 27% increase), 
or with both diseases occurring simultaneously (a 34% 
increase), require LT4 doses that are 22–34% higher to 
obtain the target TSH values. In a prospective observa-
tion in patients who developed H. pylori infection at 
that time, LT4 requirement increased significantly, the 
effect being almost completely reversible when the 
infection was eradicated. A similar phenomenon was 
observed in patients treated with proton pump inhibitor 
(omeprazole); in order to maintain target TSH values, 
it was necessary to increase the LT4 dose by 37% [39].
In a recent study, Bugdaci et al. assessed the impact 
of H. pylori infection eradication on TSH and thyroid 
hormone levels in patients with hypothyroidism who 
did not respond earlier to large doses of LT4. All patients 
manifested a significant decrease in TSH concentrations; 
21% of them, however, developed iatrogenic hyper-
thyroidism. This leads us to conclude that in patients 
taking high LT4 doses in replacement therapy of hy-
pothyroidism, H. pylori infection eradication can result 
in a significant improvement of LT4 absorption which, 
therefore, necessitates a further LT4 dose adjustment 
(reduction) [40].
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Bowel resections
In recent years, owing to the so-called epidemic of 
obesity, there has been a growing amount of bariatric 
surgery, the aim of which is to facilitate body weight 
reduction in the most obese patients. The method has 
become increasingly popular following the develop-
ment of laparoscopic techniques. Its effectiveness has 
also been confirmed by numerous literature reports [41]. 
Studies have also shown that such surgical procedures 
have an influence on drug absorption. Evidence point-
ing to a decreased absorption of various preparations 
was presented in 15 out of 22 investigations dealing with 
an analysis of patients who underwent jejunoileostomy 
(Kremen’s operation), and in one out of three studies 
concerning an analysis of patients after gastroplasty. In 
one study, no malabsorption symptoms were reported 
in patients after biliopancreatic diversion. Therefore, 
it is necessary to individually adjust the dosage and 
monitor the patient postoperatively [42].
LT4 malabsorption occurs also in patients after other 
bowel resection surgeries (in the course of so-called 
short bowel syndrome). Such patients manifest an in-
creased postoperative requirement for LT4 prepara-
tions. However, no direct correlation has been observed 
between the length of the bowel left and the LT4 dose 
absorbed [43].
A recent study by Rubio et al. concerning the LT4 
absorption test has shown that in patients who under-
went gastric bypass according to the Roux-en-Y method, 
LT4 absorption does not decrease, only that the process 
becomes slower [44].
Other causes
There are literature reports of a negative impact of 
Giardia lamblia infection and that of non-specific 
bowel inflammations on LT4 absorption [45–47]. The 
case of a 57 year-old female patient is presented, with 
well-controlled hypothyroidism over a period of six 
years, who developed gastrointestinal symptoms with 
a co-existing marked deterioration of hormonal balance. 
An adequate control of hypothyroidism using routine 
LT4 doses was restored after Giardia lamblia infection 
eradication with metronidazole [46].
Conclusions
The need to use high LT4 doses in replacement therapy 
of hypothyroidism can be the first symptom of malab-
sorption syndrome, which can be oligosymptomatic 
and previously undiagnosed. Patients taking LT4 in 
a dose of more than 2 μg/kg body weight daily, with 
persistently elevated TSH values, should be diagnosed 
with reference to pseudomalabsorption or real LT4 ma-
labsorption. The LT4 absorption test, using a high LT4 
dose, plays a role in the diagnosis of pseudomalab-
sorption which is the commonest cause of difficulties 
in obtaining euthyreosis in hypothyroid patients [48, 
49]. With patient non-compliance excluded, and real 
LT4 malabsorption confirmed, a differential diagnosis 
must take into consideration such pathologies as lactose 
intolerance, coeliac disease, atrophic gastritis, H. pylori 
infection, bowel resection postoperative state, inflam-
matory bowel disease and, finally, parasite infections.
Once lactose intolerance has been confirmed via 
a lactose absorption test, a lactose-free LT4 preparation 
and a lactose-free diet should be used in order to attain 
euthyreosis or reduce the dose of LT4 preparation. In 
coeliac disease, a gluten-free diet usually results in 
the normalisation of LT4 requirement, as does the 
eradication of H. pylori infection or one caused by para-
sites. When it comes to atrophic gastritis or inflamma-
tory bowel disease, treatment of the main disease and 
its remission can improve LT4 absorption. Patients after 
bowel surgery usually require higher than standard 
doses of LT4 to attain euthyreosis.
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